Literature DB >> 17053336

Depression vulnerabilities in patients with different levels of depressive symptoms after acute coronary syndromes.

Nina Rieckmann1, Matthew M Burg, William Gerin, William F Chaplin, Lynn Clemow, Karina W Davidson.   

Abstract

BACKGROUND: Cognitive, behavioral, and interpersonal vulnerabilities have been studied in patients fulfilling diagnostic criteria for major depression and dysthymia. The extent to which these vulnerabilities are present in cardiac patients with mild to moderate depressive symptoms--a risk factor for mortality--is unknown. Moreover, few studies have examined interrelations among depression vulnerabilities.
METHODS: A consecutive cohort of 314 patients with acute coronary syndrome completed the Beck Depression Inventory (BDI) and measures of cognitive, behavioral, and interpersonal vulnerabilities (Dysfunctional Attitudes Scale, Pleasant Events Schedule for the Elderly, Dyadic Adjustment Scale, and an inventory of role transitions) within 1 week of hospital admission. Of the patients, 166 were classified as nondepressed (BDI score, 0-4), 91 as mildly depressed (BDI score, 10-16), and 57 as moderately to severely depressed (BDI score, >16).
RESULTS: Compared with nondepressed patients, both mildly depressed and moderately to severely depressed patients exhibited higher mean levels of all vulnerabilities as well as a higher prevalence of more than one elevated vulnerability, defined by threshold scores. Vulnerabilities were only minimally interrelated (r = 0.01-0.25), and they were independently associated with mild and moderate depressive symptom status.
CONCLUSIONS: This is the first study to show that cognitive, behavioral, and interpersonal depression vulnerabilities are uniquelyassociated with concurrent depressive symptoms. There appeared to be only modest overlap between vulnerabilities, supporting the idea that depression in medically ill patients is a multifaceted phenomenon, even in the presence of minimally elevated depressive symptoms. Longitudinal studies are required before causality and treatment implications can be addressed.

Entities:  

Mesh:

Year:  2006        PMID: 17053336     DOI: 10.1159/000095441

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  6 in total

1.  Persistent depressive symptoms after acute coronary syndrome are associated with compromised white matter integrity in the anterior cingulate: a pilot study.

Authors:  Michael A Rapp; Nina Rieckmann; David A Lessman; Cheuk Y Tang; Robert Paulino; Matthew M Burg; Karina W Davidson
Journal:  Psychother Psychosom       Date:  2010-02-20       Impact factor: 17.659

2.  Depression in coronary artery disease.

Authors:  Nasser Safaie; Ahmad Reza Jodati; Mohammad Raoofi; Majid Khalili
Journal:  J Cardiovasc Thorac Res       Date:  2012-09-23

3.  AMPAkines Target the Nucleus Accumbens to Relieve Postoperative Pain.

Authors:  Chen Su; Hau Yeuh Lin; Runtao Yang; Duo Xu; Michelle Lee; Natalie Pawlak; Monica Norcini; Alexandra Sideris; Esperanza Recio-Pinto; Dong Huang; Jing Wang
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

4.  Depression following acute coronary syndrome: a Danish nationwide study of potential risk factors.

Authors:  Terese Sara Hoej Joergensen; Solvej Maartensson; Else Helene Ibfelt; Martin Balslev Joergensen; Ida Kim Wium-Andersen; Marie Kim Wium-Andersen; Eva Prescott; Per Kragh Andersen; Merete Osler
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-08-19       Impact factor: 4.328

5.  The psychosocial context impacts medication adherence after acute coronary syndrome.

Authors:  Ian M Kronish; Nina Rieckmann; Matthew M Burg; Carmela Alcántara; Karina W Davidson
Journal:  Ann Behav Med       Date:  2014-04

6.  Psychosocial vulnerabilities to depression after acute coronary syndrome: the pivotal role of rumination in predicting and maintaining depression.

Authors:  Ellen-Ge D Denton; Nina Rieckmann; Karina W Davidson; William F Chaplin
Journal:  Front Psychol       Date:  2012-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.